Dual Action Antibiotics Linking Quinolone and Oxazolidinone
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing prevalence of multi-drug resistant bacteria, such as Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus, poses a significant challenge in treating infections due to the limited effectiveness of current antibiotics, with many strains becoming resistant to multiple classes of antibiotics, including β-lactams, quinolones, and vancomycin, and the need for more effective antimicrobial agents against a wide range of pathogens.
Innovation Solution
Development of new compounds that chemically link quinolone and oxazolidinone pharmacophores through a stable linker, creating dual-action antimicrobial agents effective against multi-drug resistant bacteria, including Gram-positive, Gram-negative, and anaerobic organisms, and acid-fast organisms like Mycobacterium tuberculosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-class antibiotics are used, then treatment is simple and cost-effective, but bacteria develop resistance quickly and treatment fails against multi-drug resistant strains
Solution Approach 1:
The patent combines two distinct antibiotic pharmacophores (quinolone and oxazolidinone) into a single dual-action molecule. The quinolone moiety provides Gram-negative and atypical pathogen coverage while the oxazolidinone moiety provides Gram-positive coverage, creating a single agent with broad-spectrum activity against multi-drug resistant bacteria
Solution Approach 2:
The dual-action antibiotic molecule performs multiple antibacterial functions simultaneously: it acts as both a quinolone (inhibiting DNA gyrase/topoisomerase) and an oxazolidinone (inhibiting protein synthesis at the 50S ribosomal subunit), enabling a single drug to target multiple bacterial types and resistance mechanisms
2Reliability
If multiple antibiotics are combined to overcome resistance, then efficacy against resistant bacteria improves, but treatment complexity and risk of further resistance increase
Solution Approach 1:
Instead of administering multiple separate antibiotics, the patent merges two antibiotic classes into one chemically linked molecule. This single compound delivers dual mechanisms of action simultaneously, simplifying treatment protocols while maintaining efficacy against both Gram-positive and Gram-negative resistant bacteria
3Adaptability or versatility
If broad-spectrum antibiotics are used to cover multiple pathogens, then initial treatment coverage is adequate, but resistance develops rapidly across multiple bacterial strains
Solution Approach 1:
The dual-action molecule exhibits local quality by having different functional regions (quinolone and oxazolidinone moieties) that selectively target different bacterial groups. The quinolone portion preferentially acts on Gram-negative bacteria while the oxazolidinone portion acts on Gram-positive bacteria, providing tailored antimicrobial activity within a single molecule
Data Source
AI summary
The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria.